학술논문
SO-26 Intermittent or continuous panitumumab plus FOLFIRI for first-line treatment of patients with RAS/BRAF wild-type metastatic colorectal cancer: An update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study
Document Type
Abstract
Author
Source
In Annals of Oncology June 2023 34 Supplement 1:S172-S173
Subject
Language
ISSN
0923-7534